Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
In: Cancer Research and Treatment, Vol.55 No.4, pp.1065-1076; 001091828000001; 2-s2.0-85174642252; 196638
Online
academicJournal
Zugriff:
Hormone receptor-positive (HR+) disease is the most frequently diagnosed subtype of breast cancer. Among tumor subtypes, natural course of HR+ breast cancer is indolent with favorable prognosis compared to other subtypes such as human epidermal growth factor protein 2-positive disease and triple-negative disease. HR+ tumors are dependent on steroid hormone signaling and endocrine therapy is the main treatment option. Recently, the discovery of cyclin-dependent kinase 4/6 inhibitors and their synergistic effects with endocrine therapy has dramatically improved treatment outcome of advanced HR+ breast cancer. The demonstrated efficacy of additional nonhormonal agents, such as targeted therapy against mammalian target of rapamycin and phosphatidylinositol 3-kinase signaling, poly(ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and immunotherapeutic agents have further expanded the available therapeutic options. This article reviews the latest advancements in the treatment of HR+ breast cancer, and in doing so discusses not only the development of currently available treatment regimens but also emerging therapies that invite future research opportunities in the field. ; Y ; 1
Titel: |
Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
|
---|---|
Autor/in / Beteiligte Person: | Lee, Eunice Yoojin ; Lee, Dae-Won ; Lee, Kyung-Hun ; Im, Seock-Ah |
Link: | |
Quelle: | Cancer Research and Treatment, Vol.55 No.4, pp.1065-1076; 001091828000001; 2-s2.0-85174642252; 196638 |
Veröffentlichung: | 대한암학회, 2023 |
Medientyp: | academicJournal |
ISBN: | 978-0-01-091828-1 (print) ; 0-01-091828-0 (print) |
ISSN: | 1598-2998 (print) |
DOI: | 10.4143/crt.2023.846 |
Schlagwort: |
|
Sonstiges: |
|